PDL BioPharma Advances Nuvion(R) Into Second Pivotal Study and Celgene Corporation Will Present at the UBS Global Generic and Specialty Pharmaceuticals Conference.

0 Comments | M2 Presswire, April, 2007

M2 PRESSWIRE-30 April 2007-U.S. Equity News: PDL BioPharma Advances Nuvion(R) Into Second Pivotal Study and Celgene Corporation Will Present at the UBS Global Generic and Specialty Pharmaceuticals Conference(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:30042007 City of Industry, CA - Biotechnology industry alert provided by U.S.

Equity News. PDL BioPharma, Inc. (Nasdaq: PDLI) recently announced that the company will advance its Nuvion (visilizumab) antibody in patients with intravenous steroid- refractory ulcerative colitis (IVSR-UC) into a phase 3 program. Advancement of the program follows guidance from an independent external Data Monitoring Committee (DMC) based on a planned safety and futility assessment of data from 60 patients enrolled in an ongoing phase...

Read the rest of this article with a Free Trial at HighBeam Research.
Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:
  1. You are currently: a Guest |
  4.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)